CATALOGO DEI PRODOTTI DELLA RICERCA

FATTOVICH, Giovanna
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 18.680
EU - Europa 13.712
AS - Asia 10.879
SA - Sud America 1.282
AF - Africa 175
Continente sconosciuto - Info sul continente non disponibili 92
OC - Oceania 12
Totale 44.832
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 18.402
SG - Singapore 5.184
RU - Federazione Russa 4.271
GB - Regno Unito 3.759
CN - Cina 3.104
IT - Italia 1.129
FR - Francia 1.126
BR - Brasile 1.036
DE - Germania 887
IE - Irlanda 788
VN - Vietnam 723
SE - Svezia 705
HK - Hong Kong 702
FI - Finlandia 568
KR - Corea 404
UA - Ucraina 179
BD - Bangladesh 162
CA - Canada 152
IN - India 137
TR - Turchia 101
AR - Argentina 77
JP - Giappone 57
PL - Polonia 50
MX - Messico 44
ES - Italia 43
NG - Nigeria 43
NL - Olanda 42
IQ - Iraq 39
ID - Indonesia 37
CO - Colombia 36
EC - Ecuador 35
ZA - Sudafrica 33
AT - Austria 29
VE - Venezuela 29
PK - Pakistan 27
BE - Belgio 25
PE - Perù 22
TN - Tunisia 21
CL - Cile 20
JM - Giamaica 17
UZ - Uzbekistan 17
AE - Emirati Arabi Uniti 16
KE - Kenya 16
SA - Arabia Saudita 16
AZ - Azerbaigian 15
MA - Marocco 14
PH - Filippine 14
DZ - Algeria 13
LT - Lituania 13
MY - Malesia 12
PY - Paraguay 12
UY - Uruguay 11
IL - Israele 10
JO - Giordania 10
PS - Palestinian Territory 10
AL - Albania 9
AU - Australia 9
EG - Egitto 9
EU - Europa 9
GT - Guatemala 9
PT - Portogallo 9
SN - Senegal 9
TH - Thailandia 9
KG - Kirghizistan 8
NI - Nicaragua 8
NP - Nepal 8
RO - Romania 8
BG - Bulgaria 7
CR - Costa Rica 7
CZ - Repubblica Ceca 7
EE - Estonia 7
GE - Georgia 7
HN - Honduras 7
HU - Ungheria 7
OM - Oman 7
TT - Trinidad e Tobago 7
DO - Repubblica Dominicana 6
GA - Gabon 6
MD - Moldavia 6
SV - El Salvador 6
TW - Taiwan 6
BH - Bahrain 5
CH - Svizzera 5
GR - Grecia 5
KZ - Kazakistan 5
LB - Libano 5
LV - Lettonia 5
PA - Panama 5
RS - Serbia 5
BO - Bolivia 4
HR - Croazia 4
IR - Iran 4
NO - Norvegia 4
A2 - ???statistics.table.value.countryCode.A2??? 3
ET - Etiopia 3
MM - Myanmar 3
NZ - Nuova Zelanda 3
SK - Slovacchia (Repubblica Slovacca) 3
AO - Angola 2
BB - Barbados 2
Totale 44.716
Salva come PNG Salva come JPEG
Città #
Singapore 2.946
Southend 2.941
Jacksonville 2.519
Ashburn 2.050
Woodbridge 1.526
San Jose 1.487
Chandler 1.414
Moscow 1.250
Dallas 949
Ann Arbor 934
Houston 837
Dublin 785
Hong Kong 685
The Dalles 521
Council Bluffs 506
Verona 450
Wilmington 418
Lawrence 373
Princeton 371
Lancaster 358
Nanjing 304
Beijing 288
Jinan 274
Ho Chi Minh City 265
Sindelfingen 262
New York 257
Los Angeles 249
Shenyang 221
Buffalo 200
Hanoi 171
Kent 150
Hebei 145
Tianjin 127
Changsha 121
Helsinki 120
São Paulo 114
Milan 107
Zhengzhou 105
Santa Clara 103
Boardman 97
Haikou 91
Nanchang 90
Columbus 77
Guangzhou 76
Redondo Beach 75
Taizhou 75
Jiaxing 73
Orem 71
Annandale 70
Hangzhou 70
Ningbo 69
Taiyuan 61
Norwalk 53
Toronto 53
Seattle 52
Tokyo 51
Chennai 50
Washington 50
Chicago 46
Munich 43
Falls Church 42
Lanzhou 41
Rome 41
Brooklyn 40
Abuja 39
Philadelphia 36
Da Nang 35
Frankfurt am Main 35
Nuremberg 35
Phoenix 35
San Francisco 35
Atlanta 32
Montreal 32
Rio de Janeiro 32
Warsaw 32
Providence 31
Amsterdam 28
Haiphong 28
Stockholm 28
Manchester 27
Boston 24
Seoul 24
London 23
Belo Horizonte 22
Brussels 22
Denver 22
Fuzhou 22
Las Vegas 21
Biên Hòa 19
Brasília 19
Turku 19
Auburn Hills 18
Johannesburg 18
Naples 18
Charlotte 17
Falkenstein 17
Shanghai 17
Tashkent 17
Bologna 16
Lima 16
Totale 29.371
Salva come PNG Salva come JPEG
Nome #
Accuracy of ultrasound in the detection of liver fibrosis in chronic viral hepatitis. 375
Metodo radioimmunologico ed elettrosineresi nello studio dell'antigene Australia (HBAg) e dell'anticorpo (HBAc). Risultati comparativi 320
Progression to cirrhosis and mortality of chronic hepatiita type B: a cohort study with 25 years follow-up in Italy. 233
A 25 years longitudina study of hepatitis B e antigen positive chornic hepatitis B in italian patients 227
A randomized trial of prolonged high dose of interferon plus ribavirin for hepatitis C patients nonresponders to interferon alone. 221
The homestasis model assessment of the insulin resistance score is not predictive of a sustained virological response in chronic hepatitis C patients. 218
A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. 211
Endogenously produced TNF-α contributes to the expression of CXCL10/IP-10 in IFN-λ3-activated plasmacytoid dendritic cells 211
Protease inhibitors-based therapy induces acquired spherocytic-like anemia and ineffective erythropoiesis in chronic HCV patients 207
A randomized controlled trial of thymopentin therapy in patients with chronic hepatitis B. 203
Interleukin-28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C under real-life conditions 202
Interaction between vitamin D binding protein polymorphisms and vitamin D levels in the prediction of antiviral response in chronic hepatitis C. 201
Hepatitis C and cirrhosis 198
Accuracy of VirtualTouch Acoustic Radiation Force Impulse (ARFI) Imaging for the Diagnosis of Cirrhosis during Liver Ultrasonography 198
Effect of hepatitis B and C virus infection on the natural history of compensated cirrhosis: a cohort study of 297 patients. 196
HCV gentotype 3 and circulating squamous cell carcinoma antigen (SCCA)-IgM are independently associated with histological features of NASH in HCV infected patients. 193
[Infection due to hepatitis B virus and host immune response] 192
La regressione della cirrosi epatica: non più un mito. 192
A controlled trial of lymphoblastoid interferon for chronic anti-HBe/HBV-DNA positive hepatitis 191
Post-load insulin resistance does not predict virological response to treatment of chronic hepatitis C patients without the metabolic syndrome. 191
TLR4 rs4986790 A>G genetic polymorphisms predict liver fibrosis severity in Caucasian patients with chronic hepatitis C. 190
A long term study of hepatitis G virus coinfection in chronic hepatitis B 189
A multicenter prospective observational study to evaluate factors influencing efficacy, tolerance and compliance to antiviral treatment with interferon and ribavirin in daily clinical practice 186
Long-term outcome of chronic hepatitis B in caucasian patients: mortality after 25 years 185
A randomized trial of consensus interferon in combination with ribavirin as initial treatment for chronic hepatitis C. 184
Hepatitis C virus genotype and prognosis of compensated cirrhosis type C 183
Autoantibodies during alpha-interferon therapy for chronic hepatitis B 182
Consensus interferon (CIFN) in combination with ribavirin (RBV) for naive patients with chronic hepatitis C: a multicenter study 182
Hepatocellularcarcinoma in cirrhosis: incidence and risk factors. 182
Genetic polymorphysms of vitamin d pathway predict antiviral treatment outcome in slow responder naive patients with chronic hepatitis C 179
A randomized study comparing 48 and 96 weeks peginterferon alfa-2a therapy in genotype D HBeAg negative chronic hepatitis B. 178
Interaction between vitamin D binding protein polymorphisms and vitamin D levels in the prediction of antiviral response in chronic hepatitis C. 175
Efficacy of prolonged 5 million units of interferon in combination with ribavirin for relapser patients with chronic hepatitis C. 171
Carriage of the EGF RS4444903 A>G functional polimorphism associates with disease progression in chronic HBV infection. 171
Natural history of hepatitis B virus infection and disease 170
[Relationships between clinico-therapeutic parameters and immunological status in patients with lung cancer] 169
Natural history of hepatitis B e antigen positive chronic hepatitis B in italian patients: a 25 years longitudinal study 169
A controlled trial of alpha-2 recombinant interferon for chronic HBeAg positive hepatitis 167
Malattie autoimmuni del fegato 166
Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C 166
Autonomic dysfunction and hemodynamic derangement in cirrhotic cardiomyopathy 165
Influence of hepatitis delta virus infection on clinical outcome of compensated cirrhosis type B 164
Natural course and prognostic factors of hepatitis B. 164
Hepcidin suppression relative to iron status in patients with chronic Hepatitits C 164
Final report of a consensus interferon (CIFN) plus ribavirin (RBV) study for chronic hepatitis C (CHC) 164
Progression to cirrhosis, hepatocellular carcinoma and liver related mortality in chronic hepatitis B patients in Italy. 163
Gestione delle infezioni da virus epatite B secondo le linee guida nazionali ed internazionali. 163
Natural history of chronic hepatitis B 162
Insulin resistance is not a relevant predictor of sustained virologic response in chronic hepatitis C patients: results from the Italian hepatitis C cohort study (ITAHECS) collaborative group 162
A survey of clinical toxicity of alfa interferon in 11.241 patients with chronic viral hepatitis 162
Vitamin D binding protein gene polymorphisms and baseline vitamin D levels as predictors of antiviral response in chronic hepatitis C 162
Natural history of hepatitis B and prognostic factors of disease progression 161
PEG-interferon and ribavirin in HCV-related cirrhotic patients with profound thrombocytopenia. 161
Membrane oxidative damage causes hemolitic anemia during ribavirin therapy for chronic hepatitis C 160
A controlled trial of thymopentin therapy in HBV-DNA positive chronic hepatitis B 160
Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C 159
How to predictic the outcome of chronic hepatitis B 158
Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily clinical parameters. 158
[Presence of HBsAg and IgG on the membrane of hepatic cells in patients with acute and chronic hepatitis] 157
Efficacy of prolonged high dose of interferon (IFN) plus ribavirin in young genotype 1/4 patients with chronic hepatitis C not responding to IFN alone 157
A multicenter randomized double-blind placebo-controlled trial of interleukin-2 in chronic hepatitis B 156
-smooth-muscle actin expression in chronic viral hepatitis before and after interferon therapy 156
Efficacy and safety of consensus interferon (CIFN) plus ribavirin (RBV) for naive patients with chronic hepatitis C (CHC): final report of a pilot study 155
Relationship between HBcAg in serum and liver and HBV replication in patients with HBsAg-positive chronic liver disease 154
A seven-gene signature (Cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C 154
Incidenza e fattori di rischio di epatocarcinoma. 152
Role of membrane oxidative damage in the pathogenesis of hemolitic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection 151
Suppressor cell function in chronic active hepatitis 150
TLR4 rs4986790 A>G . genetic polymorphisms predict liver fibrosis severity in Caucasian patients with chronic hepatitis B. 150
Interferon (IFN) induction followed by prolonged high dose IFN in combination with ribavirin (RBV) for relapsers HCV patients: a randomized controlled multicenter trial 149
Hepatitis C genotypes in patients with dual hepatitis B and C virus infection 148
-smooth-muscle actin expression in chronic viral hepatitis before and after interferon therapy 148
Host genetics regulates liver fibrosis progression in patients with chronic hepatitis C (CHC) 147
Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis 146
Effectiveness of interferon alfa in caucasian patients with viral compensated cirrhosis 146
Spontaneous reactivation of hepatitis B virus infection in patients with chronic type B hepatitis 145
Natural history of chronic hepatitis B virus and Hepatitis delta virus infection and disease 145
Hepatitis C virus genotype and risk of hepatocellular carcinoma in compensated cirrhosis type C 145
Clinical and virological profiles in patients with multiple hepatitis virus infections. 145
Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage 145
Antibody dependent cellular cytotoxicity (ADCC) in acute hepatitis B and in chronic active hepatitis 144
Serum HBV-DNA in anti-HBe positive patients detected by filter and liquid phase hybridization assays 144
Reduced serum hepcidin levels in patients with chronic hepatitis C 143
[The side effects associated with the interferon-alpha therapy of chronic viral hepatitis] 142
Hepatitis B core antigen (HBcAg) in serum of patients with chronic hepatitis B detected by a modified radioimmunoassay 142
Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. 142
Effectiveness of interferon alfa on the clinical course of caucasian patients with viral compensated cirrhosis 141
Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP) 140
Suppressor cell activity in viral and non-viral chronic active hepatitis 140
Antifibrogenic effect of combination interferon plus ribavirin treatment in patients with chronic hepatitis C 140
Terapia cortisonica nella cirrosi epatica compensata. 140
Efficacy of consensus interferon (CIFN) plus ribavirin (RBV) as initial treatment for chronic hepatitis C patients: an italian multicentre study 140
Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B 139
Influence of GB virus-C/Hepatitis G Virus infection on the long term course of chronic hepatitis B 139
Carriage of the EGF rs4444903 A>G functional polymorphism associates with disease progression in chronic HBV infection. 139
Antibodies to the RNase H domain of hepatitis B virus P protein are associated with ongoing viral replication 138
Changes in serum hepatitis B virus (HBV) DNA positivity in chronic HBV infection: results of a long-term follow-up study of 138 patients 138
Delayed clearance of serum HBAg in compensated cirrhosis B:relation to interferon alpha therapy and disease prognosis 138
T and K cell function in acute and chronic hepatitis 138
Serum HBsAg loss in compensated cirrhosis B: relation to interferon alpha therapy and liver disease prognosis 138
Totale 16.942
Salva come PNG Salva come JPEG
Categoria #
all - tutte 146.819
article - articoli 64.277
book - libri 0
conference - conferenze 68.842
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 13.700
Totale 293.638
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.711 0 0 0 39 295 76 110 174 172 75 263 507
2022/20234.650 434 301 540 931 438 1.052 34 288 451 22 114 45
2023/20242.363 102 186 166 361 398 301 62 114 4 33 456 180
2024/20256.028 396 508 45 911 387 83 194 264 1.044 403 422 1.371
2025/202614.275 1.307 709 942 2.155 3.383 1.135 1.623 780 1.066 699 233 243
2026/20272.397 201 515 991 690 0 0 0 0 0 0 0 0
Totale 44.832